Table 2 Shortened adjuvant trastuzumab treatment duration and increased risk of DFS.

From: Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer

Shortened time (months)

Change in ln(HR) (regression coefficient β)

Increased relative risk of disease recurrence

Predicted DFS in the APT triala (%)

Predicted DFS in the N9831/B31 trialsb (%)

0

Ref.

0

93

74

1

0.05

5.1%

93

73

3

0.15

16%

92

70

6

0.30

35%

91

66

9

0.45

57%

89

60

  1. aIn the 12-month trastuzumab group, 7-year DFS of 93% at baseline. None of the trial patients with node-positive disease.
  2. bIn the 12-month trastuzumab group, 10-year DFS of 74% at baseline. Patients (100%) in B-31 and 86% in N9831 trial with node-positive disease.
Back to article page